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ABSTRACT
Shingles is a prevalent disease within the overall population, and incidence in North America
continues to increase. Shingles is commonly found in older adults 60 years of age and older and
can recur two or three times. Shingrix was released in 2017 as a recombinant vaccine for
prevention of shingles. Despite its benefits, this vaccine has not been recommended by many
prescribing providers. Research has shown that an effective education program improves
attitudes and misconceptions related to vaccines and can increase prescribing rates. An
education program was created to share with prescribing providers to improve overall knowledge
and recommendation rates for the vaccine. This formal education program was designed for
prescribing providers for review in a 30-minute seminar. To determine overall effectiveness, the
program was piloted in a primary care office setting in Central Virginia. The program was found
to increase overall knowledge and appeared to increase the likelihood of recommendation. This
evidence-based practice project was consistent with established research indicating that when a
prescribing provider is informed about a vaccine, he or she is more likely to discuss it with
patients. Patients consider their prescribing provider’s opinion seriously when making decisions
about vaccines, including Shingrix.
Keywords: chickenpox, herpes zoster, immunization, recombinant zoster vaccine,
shingles, Shingrix vaccination, varicella zoster virus, Zostavax, vaccine hesitancy, vaccine
education
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SECTION ONE: INTRODUCTION
Shingles is a prevalent disease that is caused by the herpes zoster virus (Bresse et al.,
2013). This condition typically presents with symptoms of blistering rash, localized pain,
numbness, localized burning, and itching. Patients may also present with headache, nausea, and
chills (Bresse et al., 2013). This disease occurs in 2 to 4.6 cases per 1,000 individuals in patients
ages 50–79 and 10 to 12.8 cases per 1,000 individuals in patients 80 years and older.
Postherpetic neuralgia (PHN) is a common complication of shingles. Among those who are
diagnosed with shingles, 20% of patients 60 to 65 years of age and 30% of patients older than 80
years of age are diagnosed with PHN. The Shingrix vaccine is a new, attenuated (weaker)
immunization that offers protection against the shingles virus (Chan et al., 2018). Prior to Food
and Drug Administration approval on October 23, 2017, the live vaccine Zostavax was the best
prevention against shingles (GlaxoSmithKline, 2017). Shingrix is more than 90% effective in
preventing shingles and PNH in all populations and poses less risk than the live immunization,
Zostavax (Bharucha, Ming, & Breuer, 2017).
This vaccine is a priority for providers to be educated about because it was released for
public use less than two years ago (GlaxoSmithKline, 2017). Due to its recent release, many
patients are not aware of the immunization. In addition, providers are less likely to recommend
the vaccine because of time constraints during wellness visits. Providers may not have
previously researched the vaccine and therefore may not feel comfortable recommending it.
Another issue that may result in provider hesitancy to recommend the Shingrix vaccine is the
cost. According to GoodRx (2018), the average price of the Shingrix vaccine is approximately
$184.71. The vaccination is given in a two-dose series two to six months apart, and the total cost
of the Shingrix vaccine is $381.67 (GoodRx, 2018). Many insurance companies were previously
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not covering the vaccine, but recent changes have led to coverage by almost all commercial
insurances (Centers for Disease Control [CDC], 2018).
Although this vaccine is effective at protecting individuals from disease, compliance
rates for Shingrix are low. Since the Shingrix immunization was newly released in 2017, it is
possible that patients are unaware that they can have greater protection against the shingles virus.
The purpose of this scholarly project was to educate health care providers on the benefits of the
new Shingrix vaccine and increase vaccine recommendations to their patients.
Background
The prevalence of shingles is approximately 30% of the population, and 10% of these
individuals will develop PHN (Friesen, Chateau, Falk, Alessi-Severini, & Bugden, 2017). The
incidence in North America is between three and five people per 1,000 yearly (Kawai,
Gebremeskel, & Acosta, 2014). The incidence for patients age 60 and older is 10 per 1,000
individuals. Herpes zoster can also recur in second or third episodes, but the incidence for these
occurrences is unknown (CDC, 2018). One to four percent of individuals are hospitalized related
to complications, and 96 deaths per year have herpes zoster designated as the cause. Herpes
zoster rates have been increasing gradually over time (CDC, 2018). While a specific factor has
not been directly linked to the increase, a consideration is the introduction of the varicella
(chickenpox) vaccine. Some cohorts may experience an increase in shingles due to the varicella
vaccine (Rafferty, McDonald, Qian, Osgood, & Doroshenko, 2018). However, most countries
have indicated an increase regardless of varicella immunization compliance (Rafferty et al.,
2018).
Varicella zoster virus (VZV) can be spread through direct contact when an infected
individual has active lesions. In addition, hospital protocol requires airborne precautions for
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immunocompromised individuals and disseminated infections to prevent airborne transmission.
The lesions are infectious until they are dry and crusted over (CDC, 2018). This allows
transmission to individuals without previous exposure to VZV to become infected. These
individuals can present with a varicella outbreak following this exposure, which then can emerge
as herpes zoster during reactivation. Individuals who have been infected with VZV or who have
been vaccinated for varicella could develop this condition (CDC, 2018). Those who have active
lesions are advised to limit contact with others until they are dry to prevent transmission.
The most significant risk factor for shingles is previous exposure to VZV. Currently in
the United States, 99.5% of individuals 40 years of age and older have been exposed to the virus,
making them more likely to develop shingles (CDC, 2018). Risk also increases as immunity to
the virus declines and could be related to aging, immunodeficiency, immunosuppression, or
current medications (CDC, 2018). Immunosuppression and immunodeficiency may occur due to
leukemia, lymphoma, a bone marrow transplant, HIV, medications including steroids, or
chemotherapy. An individual over the age of 50 is more likely to develop shingles, and risk
continues to increase with aging. Studies have shown that women are more likely to develop this
condition than men. In addition, individuals who are Caucasian are more likely to develop
herpes zoster than those who are African American (CDC, 2018).
When VZV initially enters the body, it has an impact on the sensory neurons and skin.
The virus then becomes latent in the neuronal ganglia and stays in the ganglia permanently
(Friesen et al., 2017). The virus typically reactivates in a single ganglion, classically causing
moderate to severe pain and a maculopapular rash that follows along the dermatome (Friesen et
al., 2017). The rash typically appears with vesicles over the course of three to five days and then
begins to dry and crust over within two to four weeks (CDC, 2018). The rash may also present
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in a second nearby dermatome, and the most common area of appearance is the thoracic
dermatome (CDC, 2018). Typically, the rash does not cross midline; however, some individuals
may develop a more diffuse rash impacting three dermatomes or more. In addition to pain, a
patient may complain of itchiness or a tingly sensation at the site. Patients may also admit
generalized malaise, headache, and photophobia during the prodrome of the virus (CDC, 2018).
A mild complication of scarring or darkened pigmentation at the area of the rash may
occur (CDC, 2018). The most common complication, which impacts 10% of individuals who
are diagnosed with herpes zoster, is PHN (Friesen et al., 2017). PHN is a pain syndrome that
persists after herpes zoster has resolved due to inflammation or virus-induced nerve damage
(Friesen et al, 2017). Other complications that may occur include ophthalmic involvement
accompanied by acute or chronic ocular sequelae, bacterial infection of lesions, cranial and
peripheral nerve palsies, and, in severe cases, visceral involvement (CDC, 2018).
Prior to the introduction of the Shingrix vaccine, Zostavax was recommended by the
CDC for protection against herpes zoster (CDC, 2018). It is administered to patients 50 years of
age and older (MerckVaccines, 2018). It contains a live-attenuated VZV, or a weaker version of
the virus, to expose the patient’s body to the virus and result in the manufacturing of specific
antibodies. It is given as a single dose subcutaneously. It has a large side effect profile and
cannot be given to those who are pregnant or immunocompromised (MerckVaccines, 2018).
Shingrix is a recombinant vaccine that is given intramuscularly in two doses two to six
months apart (Deshpande, 2018). Each dose is a 0.5 mL injection (Deshpande, 2018). Patients
that are recommended to receive the vaccine are older than 50 years of age (CDC, 2018).
Patients who have had shingles in the past are encouraged to receive the vaccination as soon as
possible, as long as the acute infection has resolved. One dose allows protection for life.
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Patients should still receive Shingrix even if they have received Zostavax in the past. Common
side effects associated with the immunization include redness and edema at the injection site
(CDC, 2018). Other side effects that are associated with Shingrix include fatigue, muscle aches,
headache, chills, fever, stomach pain or nausea. The vaccine should not be administered if the
patient has ever had a severe allergic reaction such as anaphylaxis to a component of the vaccine
or the initial dose of Shingrix. Severe allergic reactions are uncommon and may present as
symptoms including hives, facial swelling, increased heart rate, dizziness, and weakness (CDC,
2018).
Problem Statement
According to the CDC (2018), Shingrix is more than 90% effective at preventing shingles
and long-term nerve pain. Despite the promising benefits of the new vaccine, many health care
providers are failing to routinely recommend vaccines to their patients. Patients have stated if
their provider discussed the immunization with them, they would be more likely to receive it
(Ridda, MacIntyre, & Lindley, 2009). Targeted interventions focusing on education for medical
providers with prescriptive authority has led to increased knowledge and improved vaccination
rates for patients (Ridda et al., 2009).
Purpose of the Project
The purpose of this project was to educate health care providers in a Central Virginia
internal medicine practice about the new Shingrix vaccine and increase recommendation of the
vaccine to their patients as a result. By assessing knowledge before and after the educational
program, the project coordinator determined the impact of the educational program. In addition,
the project coordinator was planning to utilize a pre- and post-education chart review to assess

SHINGRIX EDUCATION FOR PROVIDERS

15

provider recommendations of the vaccine. Due to unexpected factors, the project coordinator
was unable to collect this data.
Clinical Question
The clinical question was, “Does a Shingrix education program for health care providers
in a Central Virginia internal medicine practice, vs no formal education program, lead to
increased overall knowledge for prescribing practitioners and increased recommendations for
patient vaccination?”
SECTION TWO: LITERATURE REVIEW
Search Strategy
An extensive search of the literature has been performed using the “search anything” tool
bar on the Liberty University Library page. Due to the vast number of articles related to this
topic, the project coordinator needed to apply filters and search effective keywords (Moran,
Burson, & Conrad, 2017). Key words utilized in article searches include provider hesitancy,
Shingrix, barriers to vaccination, vaccination education for providers, shingles vaccination, and
immunization education. Initially, thousands of articles were identified related to the topic of the
shingles vaccine. Databases that were subsequently searched include PubMed, Ebsco, PubMed,
and CINAHL. Articles that were not published within the last 10 years were omitted by the
exclusion criteria. Other specific inclusion and exclusion criteria were not implemented, but
mainly articles that focused on education for providers about vaccination were chosen. Articles
about the Shingrix vaccine and its efficacy were also included to assist in development of the
educational program and to support the need for providers to recommend the vaccination to their
patients. Twenty-four articles were considered to support the implementation of the project.
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Critical Appraisal
To ensure that the evidence supports the scholarly project, the articles have been critically
appraised with Melnyk’s system of hierarchy (University of Michigan Library, 2019). Articles
have been analyzed systematically to consider level of evidence, strengths, and weaknesses of
the evidence. The study sample, methodology, and results have also been considered (Rousch,
2015). The articles have been included that best support this scholarly project. A table of
evidence has been included in Appendix A.
Clinical practice guidelines. A recombinant zoster vaccine (Shingrix) has been available
in the US since 2017 and is recommended by the CDC and the Advisory Committee on
Immunization Practices as the preferred shingles vaccine (CDC, 2018). Shingrix is
recommended for healthy adults 50 years and older in a two-dose series separated by two to six
months. The injection is given in the upper arm. The two doses of Shingrix are more than 90%
effective in preventing shingles and PHN. Patients may receive the Shingrix vaccine even if they
were previously vaccinated with Zostavax. Serologic testing to evaluate for the presence of
previous varicella infection is not indicated prior to vaccination with Shingrix (CDC, 2018).
Systematic reviews. A systematic review is an analysis of all relevant randomized
controlled trials (RCTs) and evidence-based clinical guidelines (Hall & Roussel, 2014).
Systematic reviews were considered to support the need for immunization with the Shingrix
vaccine. Bharucha et al. (2017) conducted a systematic review of three different studies which
focus on the general population, the elderly, and HIV-infected individuals. The purpose of this
study was to provide critical appraisal of current evidence regarding Hz/Su, or Shingrix. The
results of this study state that “Shingrix is the preferred vaccine, over Zostavax (zoster vaccine
live), a shingles vaccine in use since 2006” (Bharucha et al., 2017, p. 6). The study further
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indicated vaccine efficacy for HZ/Su [Shingrix] for participants over 50 years of age appeared to
decrease with time (Bharucha et al., 2017) from 96.6% at year 1 to 87.9% at year 4; however, the
authors concluded that the difference was not statistically significant and longer-term studies are
needed (Bharucha et al., 2017). In addition, Bharucha et al. (2017) stated that HZ/Su [Shingrix]
appears to effectively protect against VZV.
Paterson et al. (2016) reviewed 185 articles about vaccine hesitancy among health care
providers and the influence of their knowledge and vaccination behavior on their
recommendations. The researchers found that knowledge about vaccines, including their
efficacy and safety, helped to build health care providers’ confidence in vaccines as well as their
willingness to recommend vaccines to others (Paterson et al., 2016). Key recommendations from
the study included more training or information support on vaccine risks and benefits, more
patient communication tools for health care providers, and the strengthening of trust between
health care providers and health authorities (Paterson et al., 2016).
Sadaf, Richards, Glanz, Salmon, and Omer (2013) conducted a systematic review of 25
studies to identify interventions for reducing parental vaccine refusal and vaccine hesitancy. The
study found there was no evidence to support a specific intervention, but studies consistently
supported that any type of educational intervention with providers had the ability to increase
patient immunization (Sadaf et al., 2013).
Randomized controlled trials (RCTs). An RCT includes a randomized control group
and randomized experimental group. The experimental group is exposed to an intervention, and
impact of the intervention is compared to the control group (Hall & Roussel, 2014). Articles
were considered that highlight the effectiveness of the vaccine and determine the impact of
provider education on vaccination. In an RCT to determine the effectiveness of the Shingrix
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vaccine in different age groups (older than 50 years and older than 70 years), the Shingrix
vaccine was found to be effective for all patients 50 years of age and older and should be
recommended by providers (Elliott & Chan, 2018). Another study discussed the efficacy of the
Shingrix vaccine in which 29,000 subjects were studied globally to determine the effectiveness
of the vaccine. The researchers concluded that the vaccine was more than 90% effective in all
populations (Oakes, 2017). Another study conducted by GlaxoSmithKline determined that
Singrix indicated almost 70% efficacy in patients with a stem cell transplant. The purpose of this
study was also to identify the effectiveness of the vaccine (“GSK Phase III Study,” 2017).
In another RCT, Krieger, Castorina, Walls, Weaver, and Ciske (2000) sought to
determine the impact that additional education can have on vaccination rates. Participants were
65 years of age from a senior center. One group was given additional educational materials on
the pneumonia vaccine. When comparing the groups, it was found that immunization rates
increased as a result of pamphlets and other educational materials distributed to the participants.
The results indicated that materials provided to patients have an impact on decision making
related to vaccines, and providers should distribute these materials to their patients (Krieger et
al., 2000).
Dubé et al. (2016) studied research network members and health care providers to
identify the opinion of vaccination experts and health professionals related to the definition,
scope, causes, and consequences of vaccine hesitancy in Canada. Two separate surveys were
administered to randomized groups. All parties were concerned about the decline of vaccination
rates overall in Canada, but many providers stated that they felt improperly counseled to advise
vaccine hesitant patients (Dubé et al., 2016). This study supports the fact that many providers
feel improperly educated to speak with vaccine-hesitant individuals and that they require further
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education. Another RCT was conducted in Japan to determine the impact of the varicella
vaccine on the occurrence of herpes zoster. Patients were randomized from 43 clinics in Japan
and were determined to be at higher risk for shingles related to varicella vaccination and
prevalence (Toyama & Shiraki, 2018). This reinforces the need for the shingles vaccine in the
community.
Quasi-experimental. Quasi-experimental studies include research from trials that
include an intervention but are not randomized (Hall & Roussel, 2014). MacDougall et al.
(2015) conducted a study with surveys and focus groups to assess knowledge of patients and
providers related to vaccine preventable disease. Knowledge related to vaccination was lacking
in both group, which supports the need for further education for providers overall (MacDougall
et al., 2015).
Clark, Jackson, Hodges, Gilliam, and Lane (2015) conducted a quasi-experimental study
to understand the impact that vaccination education can have on a specific population. The study
participants included patients who were at risk for pneumonia and were treated in a presurgical
center. Targeted education with flyers was utilized as the intervention, which led to increased
vaccination rates. The researchers concluded that if patients are given the appropriate education
materials by their health care providers, they are more likely to be vaccinated (Clark et al., 2015).
Jones et al. (2012) conducted a research study to identify factors that influenced parents
vaccinating their children. For this study, 1,367 parents of children at 1,000 schools across
Colorado, Massachusetts, and Washington were surveyed. While patients have increased access
to health information online and through social media, research confirms that most parents obtain
and utilize information given to them by medical professionals. Additionally, the authors
concluded that if providers prioritize their own vaccination status, they are more willing to
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encourage their patients to pursue immunization (Jones et al., 2012). If patients and family view
vaccinations in a positive light, they are more likely to stay up to date with their own vaccination
status. A negative attitude toward vaccination influences patients and families to avoid updating
their immunization status. In addition, patients and families with negative attitudes may impact
the decision of others (Jones et al., 2012). The authors confirmed that providers need additional
support and guidance to help educate their patients and their parents.
Kaplan-Weisman, Waltermaurer, and Crump (2018) conducted a study to determine if
targeted interventions could increase shingles vaccination rates. A physician provided targeted
education to 103 participants from a local homeless shelter. Although the sample size was small,
the study results indicated that provider understanding of vaccinations and targeted education
was associated with an increased uptake for vaccination in vulnerable populations (KaplanWeisman et al., 2018). If the provider feels more prepared to discuss information with their
patients, education for patients is improved, and therefore vaccination levels are increased.
Prioli et al. (2018) studied the knowledge base of older adults related to vaccines. Fortyfive participants in a senior care setting were questioned about vaccines, and knowledge related
to vaccines was minimal. The study recommended that education be improved in different
settings for patients and that providers take on a larger role in ensuring that their patients are
informed (Prioli et al., 2018).
Educating new providers such as medical students is also correlated with immunization
compliance (Schnaith et al., 2018). Schnaith et al. (2018) provided 101 medical students with an
educational program catered to them to determine if the program would increase the likelihood
of the students advising their patients to be vaccinated for human papilloma virus (HPV). The
medical students indicated that following the educational program, they were more likely to
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recommend the HPV vaccine. The study results indicate that provider education increases the
likelihood of the provider to recommend the vaccination. In addition, Suryadevara. Bonville,
Cibula, and Domachowske (2019) conducted a study to determine if provider, health care staff,
patient, and parent education about the vaccine and cancer prevention improved compliance with
the HPV vaccination. The study included providers and patients from six pediatric offices in
upstate New York. The results indicated that vaccination rates for HPV increased by at least
10% in three practices and at least 5% in three practices. The study indicated that increased
provider education about the benefits of vaccination improves overall vaccination rates. Another
study by Perkins et al. (2015) tried to identify if an educational program with providers increased
overall vaccination rates for HPV in pediatric patients. Educational sessions were conducted
with the providers who volunteered, and vaccination rates were compared for patients in a
control group against those whose providers received education. Girls who were patients of the
providers in the intervention group were more likely to be vaccinated when compared with girls
in the control group. Vaccination rates for the boys stayed about the same when compared with
the control group. The study results indicate that more provider education has a positive impact
on immunization. Patients of providers who received the education were more likely to be
vaccinated.
Reiter, Stubbs, Panozzo, Whitesell, and Brewer (2011) conducted a study to determine
the impact that education related to vaccination could have on the population. The sample
included parents, school staff, and health care staff. The study results indicated that knowledge
was improved following targeted education. This study indicates that education related to
immunization is important for the community to ensure educated decision making from patients
and parents (Reiter et al., 2011). Another study was performed by Leask et al. (2012) to identify
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different parental attitudes about vaccination and how providers felt would be best to educate
parents. The study included 112 articles and then surveyed 103 immunization providers. Five
specific parental opinions regarding vaccinations were identified, and providers determined that
a guiding-style discussion was helpful in talking to parents. The researchers concluded that there
were still areas for improvement identified in provider knowledge.
Real et al. (2017) conducted a study with 45 residents working at the Cincinnati
Children’s Hospital Medical Center pediatric primary care center to identify the impact of a
virtual reality educational program related to vaccines. The intervention group received the
virtual reality training. The study results showed a decrease rate of vaccine refusal for the
patients of the residents that were enrolled in the educational program. The researchers
concluded that improved provider education increases providers’ personal knowledge and leads
to increased vaccination rates (Real et al., 2017).
Other evidence. Articles from systematic reviews of qualitative studies, quantitative
studies, and expert opinions are included in this section. Qualitative studies present
nonnumerical data correlated with an intervention (Hall & Roussel, 2014). Expert opinion is
information presented by a credible source related to the topic (Hall & Roussel, 2014). An
article by Bowser (2017) discusses how 15 experts were asked to vote to determine if the
Shingrix vaccine should be recommended to patients. The advisory panel voted to recommend
the Shingrix vaccine over the Zostavax when it was released (Bowser, 2017). The Shingrix
vaccine was also supported by the CDC and recommended by experts affiliated with the
European Union (Zacks Equity Research, 2018).
Qualitative research indicates the need for increased education for providers and confirms
the positive impact that it has on patients (Busby, 2018). In coming to this conclusion, Busby
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(2018) surveyed residents of British Columbia to examine reasons behind the decreased rates of
adult vaccination in Canada. Patients who were vaccinated stated that their health care provider
recommended it to them. People that indicated they were not vaccinated felt as though they did
not have access to all recommended vaccines.
Loehr and Savoy (2016) discussed methods to encourage vaccine-hesitant patients and
families and to address their concerns. The authors stated, “Cultural pressure, misinformation,
and fear of harm are a few reasons why patients may hesitate to agree to vaccination” (Loehr &
Savoy, 2016, p. 95). Models have been proposed on managing vaccine hesitancy, including the
three Cs (Confidence, Complacency, Convenience), the CASE approach (Corroborate, About
me, Science, Explain/Advise), and the 3 As (Ask, Acknowledge, Advise). They concluded that
research supports the physician’s recommendation as the most important reason a patient accepts
an immunization (Loehr & Savory, 2016).
In another qualitative study, Ridda et al. (2009) interviewed elderly patients admitted to
an 800-bed hospital to identify attitudes toward vaccination and determine why many individuals
were not immunized. Patients interviewed stated that one of the reasons that they did not
consider the vaccination was that their provider did not recommend it. In addition, patients were
afraid to develop the illness from the vaccine (Ridda et al., 2009). The authors concluded that
providers are not consistently recommending immunizations to their patients according to the
guidelines.
A descriptive study was utilized by Jacobson, St. Sauver, and Rutten (2015) to discuss
the best response to vaccine hesitancy from parents and patients. The researchers examined
existing systematic reviews related to this topic. Findings from the study that were indicated to
improve vaccination rates include usage of point-of-care reminders, reminder recall, provider
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positive attitudes about vaccination, and communications and standing orders implemented by
the physician. Further studies indicate that vaccinated health care providers are more likely to
recommend vaccination to others. The authors stated that primary prevention is best supported
through education by the patient’s health care provider (Jacobson et al., 2015).
Synthesis
Vaccinated health care providers. If providers prioritize their own vaccination status,
they are more willing to encourage their patients to pursue immunization (Jones et al., 2012).
The provider can also share with the patient or family that their own immunization status is up to
date (Jacobson et al., 2015). If a provider is willing to personally experience the potential side
effects related to immunization, the patient and family is more likely to trust his or her
recommendations (Jacobson et al., 2015). Due to the impact of the provider’s immunization
status on patient compliance, the prescribing provider should continue to update his or her
immunization status as necessary.
Patient attitudes. Another factor that supports vaccination is positive attitudes about
vaccination by patients (Jacobson et al., 2015). A recent study was conducted to determine the
impact of the patient and family’s attitudes on vaccination (Jones et al., 2012). If patients and
family view vaccinations in a positive light, they are more likely to stay up to date (Jones et al.,
2012). A negative attitude toward vaccination influences patients and families to avoid updating
their immunization status. In addition, patients and families with negative attitudes may impact
the decisions of others.
Vaccine recommendations by health care providers. Patients have stated that if their
provider discussed an immunization with them, they would be more likely to receive it. Many
patients who are not vaccinated state that they did not pursue vaccination because their primary
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care provider did not discuss it with them (Ridda et al., 2009). Prioritizing discussions about
updating vaccination will lead to increased immunization compliance (Clark et al., 2015). By
increasing provider education, the project coordinator hoped to improve the number of providers
that recommend the vaccine to their patients.
Preparedness of providers. As indicated in the study that focused on education for
medical students, many providers feel unprepared to recommend a vaccination to their patients
(Schnaith et al., 2018). In addition to medical students, many practicing providers may not feel
educated enough to recommend a vaccine (MacDougall et al., 2015). The Shingrix vaccine is a
recently released vaccination and providers may not feel as though they are prepared to discuss
the risks and benefits with patients and families. Further education for providers is indicated to
have a positive impact on immunization (Perkins et al., 2015).
Interventions to increase vaccine uptake by health care providers. Overall
immunization rates have been lower when compared to the previous decade, but targeted
interventions focusing on education for providers has been able to lead to increased knowledge
and in turn improve vaccination rates for patients (Ridda et al., 2009). Interventions include a
focused education program for providers and health promotion education (Perkins et al., 2015).
All studies that included a specific education program resulted in an increase in vaccination
rates.
Conceptual Framework
The Iowa Model was implemented within this scholarly project and started by analyzing
the triggers that were present, leading to the creation of the evidence-based practice (EBP)
project (Hall & Roussel, 2014). The integral steps that are associated with the Iowa Model in
research include identifying a trigger, determining organizational priority, formulating a team,
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examining the evidence, implementing a change into practice, and analyzing the outcomes (Hall
& Roussel, 2014). Permission was provided by the University of Iowa Department of Nursing to
utilize the Iowa Model for this scholarly project; see Appendix B.
While the other models provide effective policy change, they do not allow for thorough
evaluation throughout the process. It is important that a successful screening and education
program is formulated to ensure that resources are utilized effectively (Hall & Roussel, 2017).
The Iowa Model allows for evaluation and stepwise change to ensure that any issues with a new
policy are identified and solved.
Considering current issues and existing research allows for practice change in a
procedural fashion (Hall & Roussel, 2014). There are both problem- and knowledge-based
triggers identified related to this topic, and the Iowa Model effectively evaluates them and the
potential opportunities for change. The knowledge-based trigger was identified when the project
coordinator was informed about the release of the new vaccine. The problem-based trigger was
identified at the practice setting because the project coordinator completed clinicals at the setting
and determined that the vaccine was not regularly being recommended by providers. These
triggers are the reason that this specific change was a focus within this setting (Hall & Roussel,
2014).
In addition to the existing triggers, the Iowa Model also considers the drawbacks and
benefits of a change to the health care organization as a whole (Hall & Roussel, 2014). This is
identified in the Iowa Model as determining the organizational priority. The organizational
priority is to provide excellent care for life. By prioritizing education for providers about the
Shingrix vaccine, the project coordinator is supporting vaccine compliance for patients. This
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ensures that the goals of the project coordinator match that of the health care organization before
the change.
A team was created in order to support the implementation of the project (Hall &
Roussel, 2014). New ideas and changes in a practice setting should be supported by others, as an
idea that is supported by a group will be more successful. Support by a group allows for
effective uptake of a change in practice (Hall & Roussel, 2014). The project coordinator
recruited the office manager and a lead physician to support development of the project.
The project coordinator then considered existing literature (Hall & Roussel, 2014). If
research had not been adequate or indicated that a different change would have been more
favorable, then the project would have been put on hold (Hall & Roussel, 2014). The project
coordinator evaluated the literature with an extensive search utilizing the identified key terms.
This provided reinforcement from other studies that the proposed change would be effective,
leading to better patient care.
After the evidence is analyzed, the change can then be tested in practice. Typically, a
change is tested as a pilot and occurs on a smaller scale (Hall & Roussel, 2014). The pilot stage
is utilized to ensure that the new process is effective. This EBP project was implemented as a
pilot because it was integrated into one internal medicine practice. The practice is a part of a
care network, and implementing the project in one setting is considered a pilot. Seven providers
were included in the pilot stage. This stage was monitored to determine if adjustments to the
process should be implemented (Hall & Roussel, 2014).
After the pilot change in practice occurred, the project coordinator evaluated if the
change would be effective in the setting and on a larger scale (Hall & Roussel, 2014). This
involved the coordinator analyzing the outcomes and considering the information obtained.
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Thoroughly analyzing the outcomes allowed the project coordinator to confidently support a
change of practice. The project coordinator has analyzed the results of the pilot study.
This concludes the six-step process to effectively integrate a change in practice (Hall &
Roussel, 2014). Throughout the project, evaluation and monitoring occurred, and new research
related to the topic will also be considered. The main strength of this model is the investigation
of the research and reevaluation of the change; however, an EBP project that follows the Iowa
Model typically requires more time and resources when compared to other models.
Summary
Immunization is a priority to support health promotion in patients. The Shingrix
vaccination has been recommended by the Food and Drug Administration, and studies have
continually supported its effectiveness (Bharucha et al., 2017). Due to its effectiveness, it should
be recommended for all patients over the age of 50 who are at risk for developing shingles
(Bharucha et al., 2017). Considering the development of vaccine hesitancy, providers have the
responsibility to educate their patients.
The purpose of this literature review was to identify evidence-based strategies to help
increase Shingrix vaccinations. Research indicates that providers feel unprepared and may
require further education before recommending a new vaccination to others. Targeted
educational programs for providers have been portrayed as an effective intervention to improve
compliance with vaccination. An educational program focused on the Shingrix vaccine is
suspected to also have a positive impact. The literature review supports the need for this
scholarly project, whose purpose is to educate health care providers in a Central Virginia internal
medicine about the new Shingrix vaccine and subsequently increase recommendation of the
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vaccine to patients. The scholarly project utilized the Iowa Model throughout all the phases of
the project to implement and evaluate a practice change.
SECTION THREE: METHODOLOGY
Design
The purpose of this scholarly project was to determine if the implementation of a
Shingrix educational program for health care providers would increase their knowledge of the
vaccine and increase recommendation of the vaccine to their patients. This scholarly project was
conducted as an EBP project and utilized the Iowa Model of Evidence-Based Practice. The
project design was nonexperimental and was based on previously identified triggers and an
extensive literature search. The project used a provider educational intervention with up-to-date
guidelines to encourage providers to discuss and endorse the Shingrix vaccine to the
recommended patient population.
The project coordinator presented an educational program for the providers which
included information about shingles and the current CDC Guidelines for the Shingrix vaccine. A
pretest and posttest consisting of 17 questions each were utilized to determine the provider’s
knowledge of shingles and the Shingrix vaccine. The project coordinator planned to audit
patient charts according to predetermined criteria four weeks prior to the educational program
and then four weeks after the program to determine if there was an increase in provider
recommendation for the Shingrix vaccine. However, on the day of the educational program, the
project coordinator was alerted by two of the participants that collecting the data from their
electronic medical record (EMR) was going to pose a problem. Elaboration on the EMR
problem will be provided in the Intervention section.
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Measurable Outcomes
1. After completion of the educational program and feedback, providers will demonstrate an
increase in knowledge about the Shingrix vaccine. This will be evidenced by an increase
in scores on the provider posttest.
2. After completion of the educational program, providers will indicate an improvement of
opinion toward the vaccine and an increase in intent to recommend the Shingrix vaccine
to their patients, as evidenced by 90% or greater of participants answering “very likely”
to recommend the Shingrix vaccine.
3. After completion of the chart audit, providers will demonstrate an increase in
recommendations for the Shingrix vaccine over a four-week period posteducation, as
compared to the same time frame prior to the educational program.
Setting
The educational program was conducted at a Central Virginia internal medical practice
associated with a large hospital system in the area. The office is located approximately eight
miles from the city’s downtown area and cares for patients throughout the area. The office
comprises 18 providers total including medical doctors, nurse practitioners, and physician’s
assistants who treat patients 18 years of age and older. They provide patients medical care by
utilizing assessment, diagnostic testing, prescription medication, treatment, and referrals.
The primary care is affiliated with a large nonprofit hospital and health care system
located in Central Virginia. The corporation has a large network of primary care practices,
family practices, and specialists. The entire corporation is committed to excellent care. By
promoting the new Shingrix vaccine, the project coordinator supported this commitment.
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The internal medicine office operates with 18 providers including both medical doctors
and nurse practitioners. While the office is part of the larger organization, it still functions fairly
independently. Key stakeholders primarily include the 18 providers that are employed at this
location. One of the physicians helped to direct the project. The letter of support provided by
the office manager is included in Appendix C. The recruitment letter is included in Appendix D.
Population
The population of Central Virginia includes different cultures and ethnicities. The
internal medicine practice is able to service this area effectively and provide quality patientcentered care. The initial population that was evaluated in this scholarly project included the
providers that are employed by this corporation. The total number of providers that were invited
to participate was 18. The sample that is included is a convenience sample (Moran et al., 2017).
Inclusion criteria for the patient chart review was anticipated to include patients who
were over the age of 50 who presented for their annual wellness examination. In addition, the
patient needed to be a resident of the Central Virginia region and be a patient at the internal
medicine practice. The final inclusion criterion required the patient’s annual wellness
examination to occur one month prior to the educational program or one month following the
educational program.
Ethical Considerations
The scholarly project coordinator and project chair completed extensive research ethics
training to ensure protection of human subjects through the Collaborative Institutional Training
Initiative and were awarded a certificate of successful completion (see Appendix E). The project
coordinator continuously reviewed all aspects of this scholarly project to ensure ethical standards
were maintained throughout the implementation. The scholarly project was submitted to the
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Liberty University Institutional Review Board (IRB) for approval. Approval from the Liberty
University IRB was obtained, and a copy of the approval form is in Appendix F. In addition to
submission to Liberty University’s IRB, the project coordinator submitted to the site’s parent
organization’s IRB for approval. The project coordinator received approval from the
organization’s IRB, and the approval letter is included in Appendix G.
During the collection of data, the confidentiality of the provider was ensured. No
identifying information was obtained from the providers on the pretest or the posttest. The
surveys were completed anonymously. Data obtained within this project will be kept for three
years and then deleted.
Data Collection
Data were obtained from the medical providers on the pretest and posttest during the
educational intervention at the Central Virginia internal medicine practice. The data collected
will be discussed in the results section and be highlighted as they relate to outcomes and
objectives (Rousch, 2015). Quantitative comparative data were obtained to investigate the
differences between the knowledge base of the providers prior to and after the educational
program (Moran et al., 2017). An improvement in knowledge after the educational program
would meet measurable outcome one. Data were also collected related to the provider’s intent to
recommend the Shingrix vaccine. This allowed the project coordinator to evaluate the
achievement of measurable outcome two.
Measurable outcome number three was to be met utilizing data from a preintervention
chart review and a postintervention chart review to compare providers’ recommendation of the
Shingrix vaccine. The project coordinator was planning to collect data four weeks prior and four
weeks following the educational intervention. Patient data were unable to be collected due to
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unforeseen circumstances with the practice EMR. This will be discussed in greater detail in the
Project Intervention section. The project coordinator planned to use this data to determine if
measurable outcome three was achieved. The implementation of three measurable outcomes
assisted the project coordinator in determining the change in provider knowledge and
recommendation.
Tools
Demographic survey. A demographic survey was created to determine influencing
factors related to provider knowledge. These factors include age, years of practice, and areas of
practice. The survey also questioned the participants’ attendance at an in-service about the
Shingrix vaccine. The demographic survey is included in Appendix H.
Pre- and posttest tools. A pretest and posttest were developed by the project coordinator
based on the CDC guidelines for Shingrix vaccination. These surveys were created to
understand the change in providers’ knowledge after the educational session. Surveying the
providers allowed the project coordinator to collect reliable data for analysis. These tests were
created with the use of Epiform 7 software. Seveteen multiple-choice knowledge and opinion
questions surveyed the level of general information about shingles and the Shingrix vaccine held
by the providers. The same survey was administered prior to and following the intervention.
The pretest and posttest are included in Appendix I.
Retrospective audit tool. The project coordinator developed an audit tool to evaluate the
impact of the educational program four weeks prior to and four weeks after the intervention. The
tool is included in Appendix J. This tool was not used in the project since the chart analysis did
not take place.
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Intervention
The educational intervention was introduced to the provider group via 30-minute
PowerPoint presentation. The educational program was designed to provide information to the
providers on shingles and the Shingrix vaccine. Seven providers from the Central Virginia
internal medicine practice attended and completed the pretest, posttest, and the educational
intervention. It was stressed to the providers that the vaccine should result in decreased
occurrence of the disease.
In presenting the educational program, the project coordinator discussed all the points
that were covered by the pretest and posttest. General knowledge about shingles was included as
well as a comparison of Zostavax and Shingrix. Efficacy, contraindications, side effects, and
dosing were all highlighted in the program. The providers were educated on their positive
impact on patient decisions regarding vaccination. The CDC guidelines for Shingrix were also
discussed. Cost and availability of the vaccine were included in the program as well as insurance
coverage. At the conclusion of the educational program, time was provided for participant
questions. The PowerPoint slides created for the educational program are included in Appendix
K.
The internal medicine practice recently updated their EMR system. This adjustment has
prevented the providers and nurses from tracking immunizations effectively. Consultation with
providers and scribes indicated that they are recommending the Shingrix vaccine to their patients
but have not found a consistent area to chart this discussion. Due to the lack of consistency,
providers stated that they are not recording this information in the EMR. In addition, patients do
not require a prescription for the vaccine, so providers are less likely to enter this information.
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Timeline
Preparation. During this stage, the project coordinator complied research, finalized the
proposal, and implemented changes necessary before the implementation phase of the scholarly
project.
1. By May 1, 2019, complete primary defense with Dr. Moore
2. By May 1, 2019, submit proposal to Liberty University’s IRB
3. By June 1, 2019, submit proposal to site IRB
Implementation. During this stage the project coordinator presented, the Shingrix
educational program to the medical staff at the internal medicine practice in Central Virginia.
Along with the presentation, a pretest and posttest were administered to the providers. Due to
unexpected circumstances with the practice’s EMR, the project coordinator was unable to
complete the chart reviews.
1. By August 1, 2019, conduct preliminary chart review
2. By August 1, 2019, complete provider educational program
3. By August 15, 2019, conduct follow-up chart review
Evaluation. The EBP was evaluated utilizing the pretest and posttest data fathered during
the educational intervention. The data were analyzed and are reported in the results section.
1. By August 15, 2019, analyze postinterventions
2. By August 20, 2019, send scholarly project to the editor
3. By August 31, 2019, conduct the final defense with Dr. Moore
4. By September 1, 2019, complete final revisions and send to Scholars Crossing
5. By September 1, 2019, disseminate the information to involved stakeholders
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Cost-Benefit Analysis
A budget for implementation of this scholarly project was not required because there was
no cost associated. The project coordinator fulfilled the education intervention and did not
receive any pro rata payment for her services.
Data Analysis
Analysis of descriptive statistics included data from the pretest and posttest. Data were
evaluated with the use of SPSS software to analyze measurable outcomes for the project. Charts
were created to compare the differences in demographics, answers on the pretest and posttest,
and intent to prescribe the Shingrix vaccine.
Measurable outcome 1. The project coordinator reviewed the pretest and posttest results
after the educational intervention. The project coordinator utilized SPSS to review and analyze
the results on both tests and the demographic results. Through SPSS, the project coordinator
conducted a t test to assess for any statistically significant differences in knowledge between the
pretest and posttest.
Measurable outcome 2. The project coordinator assessed the providers’ intent to
recommend the Shingrix vaccine via the posttest. The project coordinator utilized SPSS to
assess the posttest intent by performing an independent t-test. The researcher sought to identify
if the provider education had an influence on provider intent to recommend the Shingrix vaccine.
Measurable outcome 3. The project coordinator was unable to gather any usable data to
meet outcome 3 since the information was not available in the practice EMR. Therefore, this
measurable outcome was not achieved. This unexpected barrier was discussed in the
intervention section and is detailed in the limitations.
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SECTION FOUR: RESULTS
Seven provider participants responded to the invitation to attend the educational
intervention. The providers were 18 years of age and older and were employed by the identified
Central Virginia internal medicine practice. The seven participants (N = 7) completed the
pretest, observed the educational program, and completed the posttest with a response rate of
100%. Six out of seven provider participants completed the demographic survey. The seven
provider participants met the inclusion criteria of being a current prescribing provider of the
internal medicine office and over 18 years of age.
Descriptive Statistics
Table 1 details the results of the demographic survey and highlights the frequency of each
answer. Additionally, it includes the data that are missing from the demographic survey. Four
participants (57%) were male, and three (43%) were female. The remaining demographic
information is found in Table 1.
Table 1
Participant Demographics
Variable
Frequency
%*
Age
31–40
1
14.3
41–50
2
28.6
51–60
2
28.6
60 and older
1
14.3
Years of licensure
0–3
2
33.3
8–11
2
33.3
16 or more
2
33.3
Primary area of practice
Primary care
5
83.3
Family care
1
16.7
Note. N =6
*Response totals do not equal 100% due to rounding.
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Table 2 displays the results of the pretest scores related to knowledge on the topic. The
questions that were answered incorrectly most frequently by participants are included. The
pretest included 12 knowledge questions and five opinion questions. On the pretest, there were
several common misconceptions identified. The questions most frequently answered incorrectly
were questions three (What is the average percentage of patients that have postherpetic neuralgia
after a shingles diagnosis?), six (How effective is Shingrix in preventing the disease?), seven
(What are the contraindications for the Shingrix vaccine?), nine (Administration is safe for
individuals who are immunocompromised), and 11 (Medicaid plans cover the Shingrix vaccine).
Table 2
Pretest Results
Question
3
Correct
Incorrect
6
Correct
Incorrect
7
Correct
Incorrect
9
Correct
Incorrect
11
Correct
Incorrect

Frequency

%

4
3

57.1
42.9

5
2

71.4
28.6

2
5

28.6
71.4

2
5

28.6
71.4

4
3

57.1
42.9

Table 3 highlights the number of total correct answers for each provider participant
within the pretest. The scores for the knowledge section range from zero to 12, the highest
possible score. One individual (14.3%) scored nine or above on the knowledge portion,
indicating that the individual was educated about the Shingrix vaccine and shingles. However,
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85.7% of individuals achieved less than nine questions correctly, indicating that their knowledge
related to shingles and the Shingrix vaccine could be improved.
Table 3
Frequency of Correct Answers on the Pretest
Number correct
Frequency
%*
5
1
14.3
6
1
14.3
7
2
28.6
8
2
28.6
*Response totals do not equal 100% due to rounding.
Table 4 shows the frequency of answers for knowledge questions included on the
posttest. All seven providers correctly answered at least 10 out of 12 of the posttest questions.
Tables for questions that all seven providers answered correctly are not included. The question
answered incorrectly most frequently was question nine, “Administration is safe for individuals
who are immunocompromised.” The project coordinator discussed the CDC guidelines related
to immunization for immunocompromised individuals but also discussed recent studies that have
shown it is safe for that population within her education program. This may have caused
confusion with the providers attending the seminar. Question three, “What is the average
percentage of patients that have postherpetic neuralgia after a shingles diagnosis?” was the only
other question answered incorrectly.
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Table 4
Posttest Results
Question
3
Correct
Incorrect
9
Correct
Incorrect

Frequency

%

6
1

85.7
14.3

4
3

57.1
42.9

Table 5 highlights the number of total correct answers for each provider participant
within the posttest. The highest possible score for questions in the knowledge section was 12.
All participants scored nine and above on the knowledge portion, indicating that they were
educated about the Shingrix vaccine and shingles. No individuals achieved less than nine
questions correctly on the posttest, which indicates that participant knowledge related to shingles
and the Shingrix vaccine improved.
Table 5
Frequency of Correct Answers on the Posttest
Correct answers Frequency
11
4
12
3
Total
7

Percent
57.1
42.9
100.0

Table 6 showcases the frequency of answers which indicated the providers’ likelihood of
recommending the vaccine in the pretest. One question asked participants how confident they
were in discussing the vaccine with patients utilizing a Likert scale which included very
confident, confident, slightly confident, and not confident. Four individuals (57.1%) answered
that they felt very confident or confident. Another question using a Likert scale which included
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very likely, likely, somewhat likely, and not likely as response options in asking providers how
likely they were to recommend the vaccine. All individuals answered that they were very likely
or likely to recommend the vaccine. The final question asked providers to respond true or false
to whether they had specific talking points when discussing the Shingrix vaccine. Five (71.4%)
of participants answered that they had specific talking points about the Shingrix vaccine.
Table 6
Pretest Opinion
Likelihood
Very likely
Likely
No response

Frequency
4
2
1

%
57.1
28.6
14.3

Table 7 displays the frequency of answers for the providers’ likelihood of recommending
the vaccine. The providers answered questions with the Likert scale and answer options
included very confident, confident, slightly confident, and not confident as well as very likely,
likely, somewhat likely, and not likely. The final question asked providers “true or false” if they
have specific talking points when discussing the Shingrix vaccine. All individuals answered that
they felt very confident or confident with vaccine recommendations. 100% of valid answers
chose that the participant was very likely or likely to recommend the vaccine. All participants
answered that they had specific talking points about the Shingrix vaccine.
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Table 7
Posttest Opinion
Likelihood
Very likely
Likely
No response

Frequency
6
1
1

%
71.4
14.3
14.3

Measurable Outcome 1
The first measurable outcome of the project was to determine the difference between the
provider scores on the pretest and the posttest after the educational intervention. After
completion of the educational program and feedback, providers demonstrated an increase in
knowledge about the Shingrix vaccine. This was evidenced by an increase in scores on the
provider posttest. To identify the impact of the provider educational session, the project
coordinator compared the frequency of correct answers in the pretest and posttest.
The project coordinator utilized the independent samples t test to compare the providers’
knowledge before and after the educational intervention. The pretest and posttest means,
standard deviations, and standard error means were recognized. Tables 8 and 9 highlight the
comparison of the obtained data.
Table 8
Mean, Standard Deviation, and Standard Error of Provider Knowledge Scores
Test
Correct
Pretest
7
Posttest
7
Note. p < .0005.

M
7.2857
11.4286

SD
1.60357
0.53452

SEM
.60609
.20203

SHINGRIX EDUCATION FOR PROVIDERS

43

Table 9
Independent T-test for Provider Knowledge
Levene’s test

t test for equality of means
95% CI

Equal
variances
assumed
Equal
variances
not
assumed

F
3.575

Sig.
.083

t
-6.485

df
12

Sig.
(2-tailed)
.000

M
difference
-4.14286

SE
difference
.63888

Lower
-5.53485

Upper
-2.75086

-6.485

7.317

.000

-4.14286

.63888

-5.64039

-2.64532

Measurable Outcome 2
Determining the impact of the provider educational session, the project coordinator
compared the providers’ opinion of and intent to recommend the vaccination prior to and
following the educational intervention. Achievement of this measurable outcome was
determined by the accomplishment of 90% of providers stating that they would be “very likely”
to recommend the vaccine. The 90% target outcome was not achieved because only 83.3% of
valid answers were indicated as “very likely.” While this measurable outcome was not met, there
was an increase in those who indicated that they were “very likely” to recommend the vaccine.
These results indicate possible clinical significance. Six providers answered that they would be
“very likely” to recommend the vaccine, one provider indicated “likely” to recommend the
vaccine, and one provider did not respond.

Measurable Outcome 3
The project coordinator had planned to conduct a chart audit to demonstrate an increase
in recommendations of the Shingrix vaccine over a four-week period posteducation as compared
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to the same time frame prior to the educational program. Providers were expected to
demonstrate an increase in recommendations for the Shingrix vaccine over a two-week period
posteducation as compared to the same time frame prior to the educational program. Patient
criteria for the chart review was to include individuals who were enrolled as patients at the
internal medicine practice, were 50 years of age or older, and were presenting for an annual
wellness exam during the defined time frame.
The chart review was cancelled when the project coordinator learned there was
insufficient EMR data related to Shingrix vaccination to allow for an effective analysis of this
outcome. Therefore, measurable outcome 3 was not met due to this unexpected factor.
SECTION FIVE: DISCUSSION
The scholarly project was created to identify the impact of a provider education program
and assess provider knowledge about the Shingrix vaccine. The project coordinator had a
positive impact on provider recommendation of the immunization as evidenced by the posttest
results. Demographic factors were also considered due to their influence on provider knowledge
and opinion. The results indicate statistical significance for an increase in provider knowledge
and reconfirmed the need for this evidence-based education intervention. The literature review
revealed extensive findings related to the Shingrix vaccine and existing vaccine educational
interventions. The strengths, limitations, and implications for practice related to this scholarly
project are discussed to provide future direction for research and practice.
Strengths
The pretest and posttest surveys were a cost-effective method used within this scholarly
project. The methodology provided for ease of pretest and posttest data collection. The project
coordinator completed the educational intervention with no financial assistance from the health
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care organization where the EBP project was conducted or an outside organization. Costs were
minimal and included printing and paper for the surveys. Data that were collected from the
pretest and posttest efficiently. The project coordinator was able to compile and analyze the data
effectively to determine significance. Based on the results, two of the project’s three measurable
outcomes were met. Education on the new Shingrix vaccine increased the postintervention
knowledge of all the providers that participated in the educational program. Posteducation, all
providers either stated they were “very likely” or “likely” to recommend the Shingrix vaccine to
their patients.
Limitations
The most significant limitation related to this scholarly project was the lack of pre- and
post-intervention patient data from the EMR. The project coordinator was unable to complete
the chart review as previously planned; therefore, the project lacked the evaluation data to
compare preintervention to postintervention provider recommendations of the Shingrix vaccine.
The health care organization recently switched to a new EMR. This adjustment has prevented
the providers and nurses from tracking immunizations effectively.
Health information from the previous charting system was scanned into the patients’ new
records, but the system is not capturing the information on the scanned document. The provider
or nurse needs to enter each immunization manually for each patient to accurately track his or
her vaccine status. In addition, the Shingrix vaccine currently has limited availability, so
providers are writing paper prescriptions for their patients rather than e-prescribing the vaccine.
The Shingrix vaccine is currently available at pharmacies without a prescription, so many
providers are discussing the immunization with their patient but are not noting this discussion in
the EMR.
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Project data show the significance of the educational program in affecting the provider’s
increased knowledge of and increased intent to recommend the Shingrix vaccine. However,
another limitation of the project was the small sample size of providers who participated in the
educational program. Providers were selected through convenience sampling and were invited,
but not required, to attend the presentation.
Implications for Practice and Research
The Shingrix vaccine has been indicated by research as more than 90% effective for
prevention against the herpes zoster virus, but due to its recent release, many providers have not
been educated on the vaccine and are wary to recommend it to their patients (CDC, 2018). This
scholarly project demonstrates the effectiveness of further education for providers about the
Shingrix immunization. Targeted interventions for immunization education lead to an increase
in provider knowledge, a change of provider opinion toward the vaccination, and an increase in
provider recommendation of the vaccination (Ridda et al., 2009).
Patients have indicated that their most trusted resource for health care information is their
primary care provider. If the patient’s primary care provider recommends the vaccine, the
patient is more likely to pursue the immunization. Shingles is a financial burden to the United
States health care system, and by the implementation of targeted vaccine education for providers,
the burden can be lessened. In-services about shingles for providers should be more accessible.
In addition, further research should be completed on educational programs that are specific to the
Shingrix vaccine as well as other new vaccines or medications. The project coordinator did not
identify any studies that include education for providers about the Shingrix immunization.
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Sustainability
Outcomes and data obtained from the scholarly project will be monitored in the original
location (Hall & Roussel, 2014). The educational program has been shared with the office
manager. The manager was informed that she can distribute the PowerPoint to the staff as a
reference. In addition, the PowerPoint presentation was shared with the lead physician in hopes
that he will share it when he trains new providers at his practice location. Appropriateness of the
scholarly project will be considered before integrating the project on a greater scale within the
defined setting (Hall & Roussel, 2014). The project has been successfully completed in one
internal medicine office location, and this project coordinator is hoping to implement the
education program in her area of future practice.
Dissemination Plan
The project coordinator is planning on partnering with the office manager at the internal
medicine practice and one of the physicians to inform health care providers of the findings of the
scholarly project. In addition, the medical director will be notified of the results. A document
has been compiled to send to the office manager including the results tables and will be sent via
email to distribute to the staff. The target audience of the email will primarily include
physicians, nurse practitioners, nurses, and physician assistants. The scholarly project will be
submitted to Liberty University’s Scholars Crossing to reach a larger audience, and the project
manager’s manuscript will be submitted to the Vaccine journal.
CONCLUSION
This scholarly project validates the need for further research and indicates the positive
impact of a focused educational intervention for providers. Due to the continuous influx of
information in health care, providers need to prioritize continuing education. Education on the
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Shingrix vaccine was highlighted due to its recent release as well as its efficacy. Currently,
prescribing providers and patients are limited by the availability of the vaccine. There is a
supply and demand imbalance, but the manufacturing company is continuing to respond to the
needs of the patient population. As the vaccine becomes more readily available, providers
should be prepared to discuss the immunization, side effects, cost, and insurance coverage.
Following education about the Shingrix vaccine, prescribing providers indicated that they were
more likely to recommend the immunization. Improved education increases a prescribing
provider’s confidence and discussion points with patients.
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Study
Results

vaccine
hesitant
parents was
identified

vaccination
can help
influence
decisions

Level of
Evidence

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.

Assess
knowledge of
patients and
providers
related to
vaccine
preventable
diseases

4023 patients
were
surveyed and
62 were
involved in
focus groups
and 1167
providers
were
surveyed and
45 were in
the focus
groups

Both surveys
and focus
groups were
utilized to
determine
knowledge of
providers and
the public

Knowledge
related to
vaccination
was lacking
in both study
groups

Level 3:
Quasiexperimental

This is a
convenience
sample.
Data was
obtained
from
providers
and patients
that reside in
Canada.

Yes, it supports
the need for
further evidence
for providers
overall.

To determine
the efficacy of
the Shingrix
vaccine.

29,000
subjects
globally

A randomized
controlled trial
determining
effectiveness

The vaccine
was more
than 90%
effective in
all
populations.

Level 2:
Randomized
controlled
trial

There was a
smaller
group of
subjects that
were
concentrated

Yes. This article
supports the
efficacy of the
vaccine, and
therefore indicates
that providers
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Sample

Methods

Study
Results

Level of
Evidence

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.

in the United
States.

should offer it to
their patients.

To evaluate
the influence
of the health
care
provider’s
opinion on
vaccination
rates

310 articles
were
included

An evaluation
of existing
research relate
to the topic
was
considered

Many factors
including
preparedness,

Level 1:
Systematic
review

Considers
many
different
factors rather
than just
knowledge
related to
vaccines

Yes, supports the
need to educate
providers to
increase vaccine
uptake.

To identify if
an educational
program with
providers
increased
overall
vaccination
rates for the
HPV vaccine
in pediatric
patients.

3961 girls
and 6910
boys from
two
community
health centers
in an inner
city
neighborhood

Educational
sessions were
conducted
with the
providers who
volunteered
from the
selected
offices, and
vaccination
rates were
compared for
patients in the

Girls who
were patients
at the
intervention
practice were
more likely
to be
vaccinated
when
compared
with the
control
group.

Level 3:
QuasiExperimental
study

Study was
not
randomized
and was only
focused in
one inner
city
neighborhoo
d.

Yes, this indicates
that more provider
education has a
positive impact on
immunization.
Patients of
providers who are
educated were
more likely to be
vaccinated.
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doi:10.1016/j.vaccine.
2014.11.021

Prioli, K., Formal, R.,
Schafer, J., Harris, L.
F., Jackson, F.,
Vertsman, R., & Pizzi,
L. (2018). Baseline
knowledge about
vaccines and vaccinepreventable diseases
among older adults:
Preliminary baseline
analysis of the vaccine
education through
pharmacists and senior
centers (VEPSC)
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doi:10.1016/j.jval.201
8.04.1031
Real, F. J., DeBlasio,
D., Beck, A. F.,

Methods

control group
against those
whose
providers
received
education.

Study
Results

To determine
the knowledge
base of older
adults related
to vaccines.

45 older
adults present
in a senior
care setting

Cohort study
that surveyed
a group of
elderly
citizens living
in a senior
care facility.

Vaccination
rates for boys
stayed about
the same
when
compared
with control.
Determined
that
knowledge
related to
vaccines in
general was
minimal.

To identify the
impact of a

45 residents
who are

Chosen
interventional

There was a
decreased

Level of
Evidence

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.

Level 3:
Quasiexperimental
study

Study was
limited to a
small study
group
located in
one area

Yes. Education
can be improved
in many different
settings for
patients by better
education.
Providers can take
on a larger role to
ensure that their
patients are
informed.

Level 3;
Quasi-

Study was
not

Yes, it indicates
that improved
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Vaccine education
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Study
Results

Level of
Evidence

group that
received
virtual reality
training was
compared to
control group

rate of
vaccine
refusal for
the patients
of the
residents that
were enrolled
in the
educational
program

experimental
study

randomized
and
controlled.

provider
educational
increases their
personal
knowledge and
leads to increased
vaccination rates.

A cohort study
that focuses
on three
different
groups and
their
education.

Indicated that
knowledge
was
improved
following
targeted
education.

Level 3:
Quasiexperimental
study

Study was
limited to
those
subjects
available.
Examines
education
related to
HPV rather
than
Shingles.

Yes. Indicates that
education related
to immunization is
important for the
community to
ensure educated
decision making
from patients and
parents.

Sample

Methods

virtual reality
educational
program
related to
vaccine

working at
Cincinnati
Children’s
Hospital
Medical
Center
(CCHMC)
pediatric
primary care
center
(PPCC).

To determine
the impact that
education
related to
vaccination
could have on
the
population.

Sample
included
parents,
school staff,
and health
care staff

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.
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Sample

Methods

Identify
attitudes
towards
vaccination,
and determine
why many
individuals
were not
immunized

Elderly
patients who
were
admitted to
an 800-bed
hospital

Open ended
interviews
were
conducted to
determine why
patients
received or
refused
vaccination.

Identify
methods to
address
parental
refusal of
vaccines

25 different
studies
relating to
this topic

Systematic
review of data
obtained

Study
Results

Patients
stated that
one of the
reasons that
they did not
consider the
vaccination
was because
their provider
did not
recommend
it. In
addition,
patients were
afraid to
develop
illness.
Evidence was
not as
convincing to
support a
specific
intervention,
but most
studies

Level of
Evidence

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.

Level 6:
Descriptive
study

This is a
lower level
of evidence
and obtained
data from
open ended
interviews.

Yes. This is a
lower level of
evidence,
however, indicates
that providers are
not consistently
recommending
immunizations to
their patients
according to
guidelines.

Level 1:
Systematic
review

Most of the
studies
evaluated by
the
systematic
review were
descriptive
studies, and

Yes. Reminders
for physicians and
provider based
education
programs were
among the
interventions that
were evaluated,
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vaccine hesitancy.
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Suryadevara, M.,
Bonville, C. A.,
Cibula, D. A., &
Domachowske, J. B.

To determine
if an
educational
program
catered to
medical
students
would
increase the
likelihood of
them advising
their patients
to be
vaccinated for
HPV
To determine
if provider,
health care
staff, patient

101 medical
students
enrolled at
the
University of
Minnesota

Pre-survey
and postsurvey were
administered
accordingly

46 providers
from 6
pediatric
offices in

A 2-phase
program was
implemented
where

Study
Results

indicated that
an
intervention
improved
parents’
intention to
vaccinate
their children
Medical
students
indicated that
following the
educational
program that
they were
more likely
to
recommend
the HPV
vaccine

Level of
Evidence

Level 3:
Quasiexperimental
study

Vaccination
Level 3:
rates for HPV Quasiincreased by
Experimental
at least 10%

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.

therefore
lower level
of evidence

and this supports
that change.

Study was
limited to
one group of
students, and
sample was
not
randomized

Yes, indicates that
provider education
increases
likelihood of the
provider to
recommend the
vaccination.

Study only
includes six
pediatric
offices.

Yes, indicates that
increased provider
education about
the benefits of

SHINGRIX EDUCATION

Article Title,
Author, etc.
(Current APA
Format)

(2019). Cancer
prevention education
for providers, staff,
parents, and teens
improves adolescent
human papillomavirus
immunization rates.
The Journal of
Pediatrics, 205.
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Methods

and parent
education
about the
vaccine and
cancer
prevention
improved
compliance
with the HPV
vaccination

upstate New
York and
their patients

providers and
staff are
educated, and
a patient and
parent
education
program is
conducted.

in three
practices and
increased by
at least 5% in
five
practices.

Determine the
impact that
varicella
vaccination
has on herpes
zoster in
Japan.

Patients
randomized
from 43
clinics in
Japan

Randomized
controlled
selection of
subjects

Indicated that
shingles has
increased
related to the
varicella
vaccine.

To determine
if the Shingrix

Experts
affiliated
with the

Expert opinion Experts
discussed the
determined
efficacy and
that they

Level of
Evidence

Study
Limitations

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.

Study is only
located in a
suburban
area in New
York.

vaccination
improves overall
vaccination rates.

Level 2:
Randomized
controlled
trial

Study is
located only
in Japan

This indicates that
shingles has
increased related
to varicella
vaccination and it
is important that
both providers and
patients are aware.

Level 6:
Descriptive
study

An expert
opinion is
not as

Indicates that the
EU also supports
marketing and
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European
Union

Methods

marketability
of the
Shingrix
vaccine

Study
Results

would
recommend
the vaccine
according to
the research
found.

Level of
Evidence

Study
Limitations

indicative of
a practice
change as a
trial or
systematic
review.

Would Use as
Evidence to
Support a
Change? (Yes
or No) Provide
Rationale.
recommendations
from the providers
for patients to be
vaccinated.
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You have permission, as requested today, to review and/or reproduce The Iowa Model of Evidence-Based Practice to Promote
Quality Care (Revised 1998). Click the link below to open.
The Iowa Model of Evidence-Based Practice to Promote Quality Care (Revised 1998)
Copyright is retained by University of Iowa Hospitals and Clinics. Permission is not granted for placing on the internet.
Citation: Titler, M. G., Kleiber, C., Steelman, V. J., Rakel, B.A., Budreau, G., Everett, L. Q., ...Goode, C. J. (2001). The Iowa
model of evidence-based practice to promote quality care. Critical Care Nursing Clinics of North America, 13(4), 497-509.
In written material, please add the following statement:
Used/reprinted with permission from the University of Iowa Hospitals and Clinics, copyright 1998. For permission to use or
reproduce, please contact the University of Iowa Hospitals and Clinics at 319-384-9098 .
Please contact UIHCNursingResearchandEBP@uiowa.edu or 319-384-9098 with questions.
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Site Approval Letter
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Appendix D
Recruitment Letter

3/29/2019
Provider of VHC Falls Church
400 S. Maple Avenue, Suite 200
Falls Church, VA 22046
Dear Provider of VHC Falls Church:
As a graduate student in the Doctoral of Nursing Practice Program at Liberty University, I am
conducting research as part of the requirements for a doctoral degree. The purpose of my
research is to identify if a Shingrix education program for providers leads to increased overall
knowledge for practitioners, and increased recommendations for patient vaccination, and I am
writing to invite you to participate in my study.
If you are 18 years of age or older, and are willing to participate, you will be asked to take a pretest, observe an educational program, and take a posttest. It should take approximately thirty
minutes for you to complete the procedures listed. Your participation will be completely
anonymous, and no personal, identifying information will be collected.
To participate, please let the researcher know you would like to be involved.
A consent document is attached to this letter for the live education program. The consent
document contains additional information about my research, please sign the consent document
and return it to me at the time of the live education program.
If you choose to participate, you will be provided with a complimentary luncheon during the
educational program.
Sincerely,
Lindsey Buzzeo
Liberty University DNP/FNP Student
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Collaborative Institutional Training Initiative Certificate

SHINGRIX EDUCATION

76
Appendix F
Liberty University IRB Approval

May 21, 2019
Lindsey Buzzeo
IRB Application 3817: Shingrix Education for Providers
Dear Lindsey Buzzeo,
The Liberty University Institutional Review Board has reviewed your application in accordance with the
Office for Human Research Protections (OHRP) and Food and Drug Administration (FDA) regulations
and finds your study does not classify as human subjects research. This means you may begin your
research with the data safeguarding methods mentioned in your IRB application.
Your study does not classify as human subjects research because evidence-based practice projects
are considered quality improvement activities, which are not considered “research” according to
45 CFR 46.102(d).
Please note that this decision only applies to your current research application, and any changes to your
protocol must be reported to the Liberty IRB for verification of continued non-human subjects research
status. You may report these changes by submitting a new application to the IRB and referencing the
above IRB Application number.
If you have any questions about this determination or need assistance in identifying whether possible
changes to your protocol would change your application’s status, please email us at irb@liberty.edu.
Sincerely,

G. Michele Baker, MA, CIP
Administrative Chair of Institutional Research
Research Ethics Office

Liberty University | Training Champions for Christ since 1971
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Site IRB Approval Letter
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Appendix H
Demographic Survey

1. How old are you?
a. 20-30 years
b. 31-40 years
c. 41-50 years
d. 51-60 years
e. 60 years and older
2. How many years have you been licensed as a provider?
a. 0-3 years
b. 4-7 years
c. 8-11 years
d. 12-15 years
e. 16 years or more
3. What is your primary area of practice?
a. Primary care
b. Family care
c. Pediatrics
d. Other specialties
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4. Have you ever practiced in any of the following areas? (select all that apply)
a. Primary care
b. Family care
c. Pediatrics
d. Other specialties
5. Have you attended an in-service education program on the shingrix vaccine in the past?
a. Yes
b. No
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Appendix I
Pretest and Posttest

1. How does shingles typically manifest in a patient according to the Centers for Disease
Control (CDC)?
a. Unilateral vesicular lesions along a thoracic dermatome
b. Disseminated papular lesions
c. Localized nummular lesions
d. Linear ulcerated lesions
2. What age is an individual at risk to be diagnosed with Shingles?
a. 40 years of age and older
b. 50 years of age and older
c. 60 years of age and older
d. 70 years of age and older
3. What is the average percentage of patients that have postherpetic neuralgia after a
shingles diagnosis?
a. 5-10%
b. 11-15%
c. 16-20%
d. 21-25%
4. The Shingrix vaccine is different from the Zostavax vaccine because it contains live
attenuated herpes zoster.
a. True
b. False
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5. What is the population age that is recommended to receive the Shingrix vaccination?
a. 40 years of age and older
b. 50 years of age and older
c. 60 years of age and older
d. 70 years of age and older
6. How effective is Shingrix in preventing the disease?
a. 90%
b. 80%
c. 70%
d. 60%
7. What are the contraindications for the Shingrix vaccine? (Select all that apply)
a. Have ever had a high fever with the Shingrix vaccine
b. Have received the Zostavax vaccine
c. Have ever had a severe allergic reaction to the Shingrix vaccine
d. Currently are diagnosed with Shingles
e. Currently are taking antiviral medications
8. What are common side effects associated with the vaccine? (Select all that apply)
a.

Arm pain at the site of injection

b. Muscle pain
c. Headache
d. Fever
e. Abdominal pain and nausea
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9. Administration is safe for individuals who are immunocompromised.
a. True
b. False
10. Medicare Part D covers the Shingrix vaccine.
a. True
b. False
11. Medicaid plans cover the Shingrix vaccine.
a. True
b. False
12. Private insurances vary on their coverage of the Shingrix vaccine.
a. True
b. False
13. How confident are you when discussing vaccine recommendations with your patients?
a. Very confident
b. Confident
c. Slightly confident
d. Not confident
14. How likely are you to recommend the Shingrix vaccine to your patients?
a. Very likely
b. Likely
c. Somewhat likely
d. Not likely
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15. How confident do you feel answering your patient’s questions about the vaccine?
a. Very confident
b. Confident
c. Slightly confident
d. Not confident
16. How confident do you feel discussing the vaccine with a patient who has refused?
a. Very confident
b. Confident
c. Slightly confident
d. Not confident
17. You have specific talking points when discussing the vaccine with patients who have
refused the Shingrix vaccine?
a. True
b. False
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Appendix J

Patient Number

Age Older than 50
Years

Inclusion Criteria:
Annual Wellness
Visit

Exclusion Criteria:
Contraindications for
the Shingrix Vaccine

Provider
Recommended
vaccine
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Appendix K
Provider Presentation
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